Portal de investigación
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Gómez-Martin C
- Sánchez A
- Irigoyen A
- Llorente B
- Pérez B
- Serrano R
- Safont MJ
- Falcó E
- Lacasta A
- Reboredo M
- Dueñas R
- Regueiro P
- Sanchez-Viñes E
- López RL
Grupos
Abstract
Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 689-697
- PubMed:
- 22855151
- Factor de Impacto:
- 0,529 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Campos de Estudio
Cita
Gómez C,Sánchez A,Irigoyen A,Llorente B,Pérez B,Serrano R,Safont MJ,Falcó E,Lacasta A,Reboredo M,APARICIO J,Dueñas R,MUÑOZ ML,Regueiro P,Sanchez E,López RL. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin. Transl. Oncol. 2012. 14. (9):p. 689-697. IF:1,276. (4).